-
Mashup Score: 9
Use of JAK inhibitors was not associated with a higher risk of all-cause mortality, major adverse cardiovascular events (MACE), and venous thromboembolism (VTE) compared to other agents in patients with inflammatory skin diseases. JAK inhibitors have a well-documented record of effectiveness against dermatological conditions, such as psoriasis, atopic dermatitis, alopecia areata, and vitiligo.
Source: www.medpagetoday.comCategories: General Medicine News, Allergy-ImmunologyTweet
#JAK inhibitors pose no higher risk of mortality, major cardiovascular events, or blood clots than other medications for inflammatory skin conditions. Stay informed! #SkinHealth #TreatmentOptions https://t.co/kvaOQBkLS5 https://t.co/h7qfHJLBBO